Provectus announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium), which has completed enrollment for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067), will be presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), to be held in a hybrid setting from March 10-11, 2022 in Barcelona, Spain and online. The abstract, which was accepted for oral presentation, is entitled: “Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy”. Intralesional (IL) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death within hours of tumor injection, and induce tumor-specific reactivity in circulating T cells within days.

This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB). In CB-refractory disease, PV-10 may restore disease-specific T cell function. PV-10 has been administered to over 450 patients with melanoma and cancers of the liver in both monotherapy and combination therapy settings.

IL PV-10 is administered under visual, tactile, or ultrasound guidance to superficial malignancies, and under CT or ultrasound guidance to visceral hepatic tumors. Systemic administration of PV-10 is undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, and as a therapeutic treatment for relapsed and refractory blood cancers.